Get started
Vor Biopharma Inc.Vor Biopharma Inc.Vor Biopharma Inc.

Vor Biopharma Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

VOR trade ideas

VOR - a b iotechnology penny stock LONGVOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is a speculative long trade for this company with products to treat leukemia ( blood cancer). Price has crossed over the POC line of the volume profile and also completed an anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying volume has increased since the earnings report showed less of a loss than forecasted. I see 30% upside to the high pivot in mid-January. In conjunction with stop- loss set at the mean anchored VWAP this is a R to r of about 3.
NASDAQ:VOR
by AwesomeAvani
VOR - LONGVor Biopharma is advancing blood cancer treatments with innovative technologies, focusing on improving care for AML, MDS, and MPN by making stem cells resistant. This method has shown promise, especially for post-transplant AML treatments. Wedbush analyst David Nierengarten is optimistic about the VBP301 trial, highlighting superior outcomes with VCAR33ALLO over autologous therapies, recommending an Outperform rating with an $11 price target. The broader consensus supports a Strong Buy rating, foreseeing significant stock appreciation to $14.42. In the short term, I'm looking for the stock to accumulate at slightly lower levels before working to the upside ($3 area), if we break through that zone we can see much higher, depending on catalysts, influenced by past positive pipeline PR. Good luck everyone. Catalyst: Vor Biopharma has initiated a phase I/II trial of VCAR33ALLO, a donor-derived CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML), with results anticipated in the second half of 2024.
NASDAQ:VORLong
by SPYDERMARKET